



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Maria Ester Bernardo

IEWP Chair (ELECTED APRIL 2025, PREVIOUS CHAIR: Bénédicte Neven)

Italy

Major achievements

2025 has been the first year for Claire Booth and myself as Co-Chair and Chair, respectively, of the IEWP of the EBMT. It has been characterised by key studies, collaborative achievements and educational events in the field of HCT and gene therapy for Inborn Errors of Immunity and Metabolism.

Several key studies have been published. The retrospective study on **haploidentical HSCT in chronic granulomatous disease** (*Blood*) has provided valuable insights into transplantation strategies in this complex Inborn Error of Immunity (IEI). Another notable retrospective study focused on **HCT outcomes in purine nucleoside phosphorylase deficiency** (*Blood*) covering both immunological and neurological aspects of the disease and highlighting how early diagnosis is critical to improve outcomes.

Other studies investigated HCT outcomes for **STAT1 gain-of-function disease following JAK inhibition bridging** (*J Hum Immun*) and **late effects after HCT in patients with HLH**, the latter in collaboration with the Histiocyte Society, PDWP, and TCWP (*JACI*). Another relevant publication focused on **clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients**, in collaboration with ESID (*Blood Advances*).

Moreover, pivotal studies are ongoing that will impact the landscape of HCT for inborn errors, including research on patients with **interferon gamma receptor 1/2 deficiencies, cartilage hair hypoplasia, FHL2 and FHL3**, and **long-term outcomes in Chediak-Higashi syndrome**.

In terms of educational events, the **25th IEWP Annual Conference** was held in Freiburg, Germany in September 2025, bringing together over 180 attendees, including 12 nurses, to share knowledge and advance the field on HCT and cellular therapies, including ex-vivo gene therapies, in these disorders. Moreover, the **third edition of IEWP Spring School** on HCT in Inborn Errors of Immunity, took place extremely successfully in Seville, Spain in April 2025 and gave the chance to over 30 international experts and junior attendees to deepen knowledge and share expertise on cellular therapies in these disorders. Indeed, many of the attendees from previous Spring Schools now sit on the IEWP Juniors Committee, helping to shape the Annual Meeting and support the community.

The IEWP continues to advance the frontiers of scientific research and clinical practice by promoting collaboration between Europe and the United States, with the goal of enhancing patient outcomes and optimising transplant protocols.

Principal research studies

[HSCT experience in patients with Interferon gamma receptor deficiencies](#)
[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Inherited disorders](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Peter Olbrich](#)

[Setting the stage for newborn screening and gene therapy: a disease-specific retrospective survey of FHL2 and 3](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Inherited disorders](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Stephan Ehl, Despina Moshous, Claire Booth, Sujal Ghosh](#)

[Allogeneic hematopoietic stem cell transplantation in cartilage hair hypoplasia \(CHH\); a joint EBMT-CIBMTR study](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Inherited disorders](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Heljä Lång](#)

[Outcome of haematopoietic stem cell transplant \(HSCT\) in patients with Chediak Higashi syndrome](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Inherited disorders](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Reem Elfeky](#)

[A prospective outcome study on patients with profound combined immune deficiency \(p-CID\)](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

-

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[Stephan Ehl](#)

Key publications

[2025](#)

[Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Other society](#)

[1st listed author](#)

[Emilie Pauline Buddingh](#)

[Journal](#)

[J Hum Immun.](#)

[2025](#)

[Late effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Complications Working Party \(CWP\)](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Kim Ramme](#)

[Journal](#)

[J Allergy Clin Immunol.](#)

[2025](#)

[Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[1st listed author](#)

[Uli S Herrmann](#)

[Journal](#)

[Blood.](#)

[2025](#)

[HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[1st listed author](#)

[Quentin Riller](#)

[Journal](#)

[Blood.](#)

[2025](#)

[Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWP](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Other society](#)

[1st listed author](#)

[Julia Fekadu-Siebold](#)

[Journal](#)

[Blood Adv.](#)

[See the full list of the IEWP 2025 publications](#)



Indicators


	2023	2024	2025
Impact factor	53.80	62.43	64.80
Oral presentations	4	4	2
Poster presentations	1	3	1
Educational events	4	1	1

Major educational events



[Event](#)

51st Annual Meeting of the FBM



[Event](#)

Inborn Errors Working Party Annual Conference



[ny](#)

[Event](#)

Inborn Errors Working Party Spring School

[Apr 27, 2025 - Apr 30, 2025 / Gerena, Seville, Spain](#)

[Discover more](#)

[VISIT THE IEWP WEBPAGE](#)